Rentsch, 2020, USA | NSAIDs | Prescribed NSAIDs in the year before diagnosis of COVID-19 14 days | Not available | Retrospective Cohort | VA national Corporate Data Warehouse | 585 | 66 | 27(4.6) | SARS-COV-2 PCR-positive | Incidence of NSAIDs use Risk of COVID-19 Hospitalisation ICU-admission | Age, sex, race, ACE/ARB use, HTN, temperature, chronic kidney disease, COPD, DM, vascular disease, systolic blood pressure, oxygen saturation, albumin, eGFR, FIB-4, hemoglobin, lymphocyte count, VACS Index score |
Alamdari,2020, Iran | NSAID | Prescribed NSAIDs in Electronic medical record | Not available | Retrospective Cohort | Hospitalized in Shahid Modarres Hospital | 459 | 61 | 139(30.3) | SARS-COV-2 PCR-positive | Incidence of NSAIDs use | Not applicable# |
Argenziano, 2020, USA | NSAIDs | Not available | Not available | Retrospective Cohort | Hospitalized at NYP/CUIMC | 1,000 | 63 | 404(40.4) | SARS-COV-2 PCR-positive | Incidence of NSAIDs use | Not applicable | |
Wong et al,2020, USA | NSAIDs | Prescribed NSAIDs in the 4 months before diagnosis of COVID-19 | Not available | Retrospective Cohort | National Health Service England database | 2,463,707 | 53 | 1,410,922 (57.2) | ICD-10 | COVID-19-related death | Age, sex, obesity, smoking, hypertension, HF, other heart disease,DM, COPD, asthma, other respiratory diseases such as cystic fibrosis, cancer, immunosuppressive conditions, current other medication use, region | |
Huh, 2020, South Korea | NSAIDs | Prescribed NSAIDs ≤ 7 days before diagnosis of COVID-19 | Not available | Case-control | National hospitalized patients in HIRA database | 5,172 | 44 | 2,883(55.7) | SARS-COV-2 PCR-positive | Incidence of NSAIDs use Risk of COVID-19 | Age, sex, region of residence, comorbidities, healthcare, utilization, hydroxychloroquine, ACEI/ARB, metformin, thiazolidinedione, statins, sirolimus, mycophenolate, amiodarone, camostat, systemic steroid | |
Reilev, 2020, Denmark | NSAIDs | Prescribed NSAIDs within 6 months prior to diagnosis of COVID-19 | Not available | Retrospective Cohort | Nationwide data in Danish | 9,519 | 49 | 5,509(58.0) | SARS-COV-2 PCR-positive | Incidence of NSAIDs use Risk of COVID-19 | Univariate analysis& | |
Jeong, 2020☯, South Korea | NSAIDs | Prescribed NSAIDs within 7 days before cohort entry | Not available | Retrospective Cohort | National hospitalized patients in HIRA database | 1,824 | 49 | 1,074(590) | SARS-COV-2 PCR-positive | Mechanical ventilation ICU admission Death Cardiovascular composite | PS matched for age, sex, health insurance type, hypertension, hyperlipidaemia, DM, asthma, COPD, malignancy, atherosclerosis, chronic renal failure, chronic liver disease, rheumatoid arthritis, osteoarthritis, gastrointestinal conditions, and ACEI/ARB, β-blockers, CCB, diuretics, nitrates | |
Lund, 2020, Denmark | NSAIDs | Prescribed NSAIDs within 30 days before diagnosis of COVID-19 (defined as current use) | Not available | Retrospective Cohort | Danish health and administrative registries | 1,120 | 54 | 655(58.5) | SARS-COV-2 PCR-positive | Hospitalisation ICU-admission Death | PS matched for age, sex, antihypertensives, antidiabetic drugs immunosuppressants, opioids, benzodiazepines,1st gen. antipsychotics 2nd gen. antipsychotics, systemic glucocorticoids, inhaled corticosteroids asthma, COPD, cardiovascular disease ischemic stroke, chronic kidney failure, liver disease, alcohol related disorders dementia, cancer, overweight or obesity, Hemiplegia and paraplegia, osteoarthrosis rheumatoid arthritis, dysmenorrhea | |
Nguyen, 2020, USA | NSAIDs | Prescribed NSAIDs in Electronic medical records | Not available | Retrospective Cohort | Hospitalized in University of Chicago Medical Center | 689 | 55 | 393(57.0) | SARS-COV-2 PCR-positive | Incidence of NSAIDs use | Not applicable | |
Chang, 2020,USA | NSAIDs | Prescribed NSAIDs 90 days before diagnosis of COVID-19 | Not available | Case-control Cohort | UCLA Health System | 843 | 49 | 438(52.0) | SARS-COV-2 PCR-positive | Incidence of NSAIDs use Risk of COVID-19 Hospitalisation Severe covid-19 | Age, sex, CAD, congestive HF, COPD, type 2 DM, hyperlipidemia, HTN, obesity, and chronic renal disease | |
Ramachandran, 2020, USA | NSAIDs | Prescribed NSAIDs in Electronic medical records | Not available | Retrospective Cohort | hospitalized in care academic medical center in Brooklyn | 295 | 66 | 133(45.0) | SARS-COV-2 PCR-positive | Incidence of NSAIDs use | Not applicable | |
Ruiz-Antorán, 2020, Spain | NSAIDs | Prescribed NSAIDs in Electronic medical records | Not available | Retrospective Cohort | hospitalized in 18 tertiary Spanish hospitals | 506 | 67 | 182(36.0) | SARS-COV-2 PCR-positive | Incidence of NSAIDs use Death | Univariate analysis | |
Chow, 2020, USA | Aspirin | Administration aspirin within 24 hours to 7 days before hospital admission | Not available | Retrospective Cohort | Hospitalized COVID-19 patients in CRUSH COVID study | 412 | 60 | 168(40.8) | SARS-COV-2 PCR-positive | Incidence of NSAIDs use Mechanical ventilation ICU-admission In-hospital mortality | Age, BMI, ethnicity, HTN, DM, CAD, Beta Blocker, Renal Disease | |
Choi, 2020, Korea | Ibuprofen | Prescribed NSAIDs in medical records | Not available | Retrospective Cohort | hospitalized Armed Forces Daegu Hospital | 293 | 29 | 79(27.0) | SARS-COV-2 PCR-positive | Incidence of NSAIDs use | Not applicable | |
Bruce, 2020, UK | NSAIDs | Prescribed NSAIDs prior to admission | Not available | Retrospective Cohort | hospitalized in COVID-19 in Older People study | 1,222 | 61 | 532(43.5) | Clinical or laboratory confirmed diagnosis of COVID-19 | In-hospital mortality | Age group, sex, smoking status, CRP levels, diabetes, hypertension, CAD, reduced renal function | |
Imam, 2020, USA | NSAIDs | Prescribed NSAIDs in Electronic medical record | Not available | Retrospective Cohort | hospitalized in Beaumont Health’s eight hospitals | 1,305 | 61.0 | 603(46.2) | SARS-COV-2 PCR-positive | Incidence of NSAIDs use Death | Age greater than 60 years, Comorbidities were computed into the Charlson Comorbidity Index ACEI/ARB | |
Sahai, 2020, Cleveland | Aspirin | Prescribed aspirin new or ongoing administration during admission | 81 mg | Retrospective Cohort | Hospitalized Cleveland Clinic patients | 1,994 | 60 | 1,018(51) | SARS-COV-2 PCR-positive | Incidence of NSAIDs use Mortality Safety outcomes | Propensity matched for age, platelets, gender, race, ethnicity, smoking,, oppressors, COPD, emphysema, asthma, diabetes, hypertension, CAD, HF, cancer, ongoing immunosuppressive treatment | |
Subudhi, 2020, USA | NSAID | Prescribed NSAIDs in medical record | Not available | Retrospective Cohort | Massachusetts General Brigham Healthcare database | 1,144 | > 60 | 515(45.0) | SARS-COV-2 PCR-positive | Incidence of NSAIDs use ICU-admission Death | Univariate analysis | |
Abu Esba, 2020, Riyadh | NSAIDs | Prescribed NSAIDs for 30-days in a 6-month before admission or patient self-reported chronic use. or NSAIDs use during admission | Not available | Prospective Cohort | King Abdulaziz Medical City and King Abdullah Specialist Children’s Hospital | 503 | 50 | 215(42.7) | SARS-COV-2 PCR-positive | Incidence of NSAIDs use Hospitalisation Mechanical ventilation Severe COVID-19 30-day mortality | Age, sex, comorbidities: hypertension, DM, dyslipidemia, asthma or COPD, cardiovascular disease, renal or liver impairment, and malignancy | |
Castro,2020, USA | Ibuprofen | At least one prescription or medication order of NSAIDs in the 1 year to 30 days before COVID-19 admission | Not available | Retrospective Cohort | Hospitalized in 2 academic medical centers and 4 community affiliate hospitals | 7,360 | > 60 | 3,495(47.5) | SARS-COV-2 PCR-positive | Incidence of NSAIDs use mechanical ventilation ICU death | Age at admission, gender, race, ethnicity, Charlson comorbidity index and the presence of a prior diagnosis in the health system | |
McKeigue,2020, Scotland | NSAIDs | Prescribed NSAIDs in a 240-day before diagnosis of COVID-19 | Not available | Case-control | REACT-SCOT study | 2,378 | NA | NA | SARS-COV-2 PCR-positive | Incidence of NSAIDs use Severe covid-19 | Proton pump inhibitors, antihistamines, antipsychotic drugs, and opioid analgesics | |
Osborne,2020, USA | Aspirin | Prescribed aspirin up to 30 days before diagnosis of COVID-19 | Not available | Retrospective Cohort | VA national Corporate Data Warehouse | 26,346 | 58 | 2,859(10.9) | SARS-COV-2 PCR-positive | Incidence of NSAIDs use 30-day mortality | Age, gender, and CAN* mortality score | |
Meizlish,2020,USA | Aspirin | In-hospital aspirin use | Not available | Retrospective Cohort | Yale New Haven Health System | 2,785 | > 60 | 1,389(49.9) | SARS-COV-2 PCR-positive | In-hospital death | Propensity matched for age, BMI, DDmax, admission RI score, male sex, and African-American race | |
Jehi,2020, Cleveland | NSAID | Prescribed NSAIDs in Electronic medical record | Not available | Retrospective Cohort | Inpatient or outpatients in Cleveland Clinic | 4,536 | NA | 2,426(53.5) | SARS-COV-2 PCR-positive | Incidence of NSAIDs use Hospitalisation | Univariate analysis | |
Rinott, 2020, Israel | Ibuprofen | Use Ibuprofen within a week before diagnosis of COVID-19 | Not available | Retrospective Cohort | Shamir Medical Centre | 403 | 45 | 220(54.6) | SARS-COV-2 PCR-positive | Incidence of NSAIDs use mechanical ventilation Severe COVID-19 Death | Univariate analysis | |